Is Zimmer Biomet Holdings (ZBH) Undervalued Following Its Dividend Declaration?
Zimmer Biomet Holdings (ZBH) has declared a cash dividend of $0.24 per share, with an ex-dividend date of September 30, 2026. This payout decision gives investors fresh information on the company’s capital return approach.
Recent trading has been softer for Zimmer Biomet Holdings, with the share price down 10.52% over the past 30 days and 3.66% over 90 days. This has contributed to a 6.53% decline in 1-year total shareholder return versus a relatively flat year-to-date share price move of 0.37%, which suggests momentum has been fading despite ongoing product and technology updates.
Scan for other medical technology and healthcare stocks where capital returns and recent share price moves are starting to line up by using our hand picked 38 healthcare AI stocks.
Zimmer Biomet Holdings now trades well below both analyst targets and some intrinsic value estimates, after a weak share price stretch. The key question is whether that gap reflects an opportunity or a lingering mispricing of risk.
Most Popular Narrative: 16.6% Undervalued
Zimmer Biomet Holdings is priced at $89.69 against a widely followed fair value estimate of $107.57, which presents the current weakness in the share price as a valuation gap rather than only a sentiment issue.
The current valuation implies that the market is not fully crediting Zimmer Biomet for raised 2026 growth and EPS guidance, stronger free cash flow, and higher planned share repurchases. Taken together, these factors suggest a more optimistic view of the share price than is currently reflected.
See why 34 investors see Zimmer Biomet Holdings as 17% undervalued.
Result: Fair Value of $107.57 (UNDERVALUED)
Still, the Zimmer Biomet Holdings story can change quickly if pricing headwinds keep pressuring margins or if manufacturing restructuring disrupts operations and cash generation.
Find out about the key risks to this Zimmer Biomet Holdings narrative.
Next Steps
Mixed signals can feel uncomfortable, especially when Zimmer Biomet Holdings shows both flagged issues and appealing upside markers in the data. Act quickly: review the full risk and reward breakdown, and pressure test your own stance with the 3 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Zimmer Biomet Holdings?
If Zimmer Biomet Holdings has you thinking more broadly about opportunity and risk, do not stop here. Cast a wider net and let data help you spot what others might miss.
- Target fresh underpriced potential by running your filters through the 30 high quality undervalued stocks and see which stocks currently offer more value for each dollar you commit.
- Prioritise resilience and capital strength by scanning our list of solid balance sheet and fundamentals (24 results) so you can focus on businesses that back their story with sturdier finances.
- Hunt for potential future market favourites by checking the 16 high quality undiscovered gems before attention shifts and competition for these ideas tightens.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com